[Kidney damage in primary antiphospholipid syndrome].
OBJECTIVE
To characterize clinical manifestations, course and laboratory signs of nephropathy in primary antiphospholipid syndrome (PAS).


METHODS
6 patients with PAS and renal affection were observed for 10 years since 1991. They were examined for anticardiolipin antibodies and/or lupus anticoagulant. Renal tissue was studied morphologically in one patient.


RESULTS
In all the patients renal damage manifested with arterial hypertension associated with isolated proteinuria. The majority of the patients had renal dysfunction. All of them had elevated level of antibodies to cardiolipin primarily in combination with lupus anticoagulant. Histological changes of renal tissue presented with thrombotic microangiopathy of glomerular and extraglomerular vessels, intimal proliferation and vascular wall thickening with occlusion of their lumen which combined with morphological indicators of focal segmental glomerulosclerosis.


CONCLUSIONS
The thrombotic process in the intrarenal vessels in PAS dictates the necessity to develop novel approaches to treatment of such patients. In addition to immunodepressants the treatment should include indirect anticoagulants and antiaggregants.
Kozlovskaia
N L
NL
Tareeva
I E
IE
Kamyshova
E S
ES
Varshavskiĭ
V A
VA
Miroshnichenko
N G
NG
Kotliarova
G V
GV
D000328:Adult; D017153:Antibodies, Anticardiolipin / Q000032:analysis; D016736:Antiphospholipid Syndrome / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D001706:Biopsy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007668:Kidney / Q000473:pathology; D007674:Kidney Diseases / Q000209:etiology* / Q000473:pathology; D016682:Lupus Coagulation Inhibitor / Q000032:analysis; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D017153:Antibodies, Anticardiolipin; D007166:Immunosuppressive Agents; D016682:Lupus Coagulation Inhibitor
Porazhenie pochek pri pervichnom antifosfolipidnom sindrome.